Expression of IGFBP in hepatocellular carcinoma based on bioinformatics study and its prognostic value

doi:10.3877/cma.j.issn.2095-3232.2020.06.022

Abstract

Abstract:

Objective

To explore the expression level and prognostic value of insulin-like growth factor binding protein (IGFBP) family members in hepatocellular carcinoma (HCC) by bioinformatics analysis.

Methods

The expression levels of IGFBP family members in HCC were analyzed by GEPIA online analysis. The relationship between IGFBP and clinical prognosis was assessed by Kaplan-Meier survival curve. The changes of IGFBP genes in HCC patients were observed by cBioPortal for Cancer Genomics. IGFBP-related gene network was constructed by GeneMANIA. Gene ontology (GO) enrichment analysis was performed by Metascape database.

Results

GEPIA online analysis showed that the relative expression of IGFBP3 mRNA in HCC was significantly lower than that in normal liver tissues (P<0.05). The expression of IGFBP3 was significantly correlated with the pathological stage of HCC (F=5.52, P<0.05). Kaplan-Meier survival analysis demonstrated that the expression levels of IGFBP3 and IGFBP4 mRNA were significantly associated with poor prognosis (HR=1.50, 0.43; P<0.05). cBioPortal analysis revealed that genetic changes of IGFBP in HCC including mutation, fusion, amplification, deep deletion and multiple changes, among which mutation, amplification and deep deletion were the most common changes. The genetic changes of IGFBPs were ranged from 0 to 1%. GeneMANIA analysis identified 20 genes were closely correlated with IGFBPs. GO enrichment analysis found that IGFBP was mainly expressed in the signaling pathways related to growth and cell movement.

Conclusions

Bioinformatics-based study demonstrates that IGFBP3 is abnormally expressed in HCC tissues, which is associated with clinical prognosis of HCC patients. IGFBP3 might serve as a biomarker for clinical prognosis anda potential therapeutic target in HCC patients.

Key words: Carcinoma, hepatocellular, Insulin-like growth factor binding proteins, Prognosis, Computational biology

Bin Dai, Zaixing Wang, Dandan Ma, Weidong Jin, Zhiyong Zhang, Desheng Wang. Expression of IGFBP in hepatocellular carcinoma based on bioinformatics study and its prognostic value[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(06): 602-608.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2020.06.022

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2020/V09/I06/602

Figures/Tables 6

References 15

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis[J]. Cancer Biol Med, 2018, 15(2):124-136.
[3]	Hu Q, Zhou Y, Ying K, et al. IGFBP, a novel target of lung cancer?[J]. Clin Chim Acta, 2017, 466:172-177.
[4]	Kubasiak JC, Seder CW, Pithadia R, et al. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2015, 149(3):727-734, e1-3.
[5]	Huynh H, Chow PK, Ooi LL, et al. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation[J]. Cell Growth Differ, 2002, 13(3):115-122.
[6]	Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-102.
[7]	Sharma J, Gray KP, Evan C, et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival[J]. Prostate, 2014, 74(3):225-234.
[8]	Dai B, Ruan B, Wu J, et al. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma[J]. Int J Clin Exp Pathol, 2014, 7(9):5645-5654.
[9]	Yao X, Sun S, Zhou X, et al. IGF-binding protein 2 is a candidate target of therapeutic potential in cancer[J]. Tumour Biol, 2016, 37(2):1451-1459.
[10]	Wang J, Hu ZG, Li D, et al. Gene expression and prognosis of insulinlike growth factorbinding protein family members in nonsmall cell lung cancer[J]. Oncol Rep, 2019, 42(5):1981-1995.
[11]	Wang H, Wang H, Li K, et al. IGFBP-3 is the key target of sanguinarine in promoting apoptosis in hepatocellular carcinoma[J]. Cancer Manag Res, 2020(12):1007-1015.
[12]	Mosig RA, Lobl M, Senturk E, et al. IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer[J].J Ovarian Res, 2012, 5(1):3.
[13]	Ueno K, Hirata H, Majid S, et al. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma[J]. Int J Cancer, 2011, 129(10):2360-2369.
[14]	Lee YY, Mok MT, Kang W, et al. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis[J]. Nucleic Acids Res, 2018, 46(17):8832-8847.
[15]	Butt AJ, Dickson KA, McDougall F, et al. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo[J]. J Biol Chem, 2003, 278(32):29676-29685.

基因	HR	P值
IGFBP1	0.77	0.140
IGFBP2	1.10	0.700
IGFBP3	1.50	0.027
IGFBP4	0.65	0.015
IGFBP5	0.98	0.890
IGFBP6	1.20	0.320

基因	HR	P值
IGFBP1	0.77	0.140
IGFBP2	1.10	0.700
IGFBP3	1.50	0.027
IGFBP4	0.65	0.015
IGFBP5	0.98	0.890
IGFBP6	1.20	0.320

Please choose a citation manager

Content to export